Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLDI
stocks logo

CLDI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Calidi Biotherapeutics Inc (CLDI.A) is -0.26, compared to its 5-year average forward P/E of -1.30. For a more detailed relative valuation and DCF analysis to assess Calidi Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.30
Current PE
-0.26
Overvalued PE
0.83
Undervalued PE
-3.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CLDI News & Events

Events Timeline

(ET)
2025-11-10
08:17:32
Calidi unveils fresh findings on CLD-401 at the 2025 SITC annual conference.
select
2025-10-30 (ET)
2025-10-30
08:14:44
Calidi to Present New Data on CLD-401 at the 2025 SITC Conference
select
2025-10-22 (ET)
2025-10-22
08:08:10
Calidi Reveals Establishment of Its Scientific Advisory Board
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-14Newsfilter
Calidi Biotherapeutics Announces Financial Results and Key Operational Updates for Q3 2025

  • New Data Presentation: Calidi Biotherapeutics presented promising preclinical data on CLD-401 at the SITC annual meeting, showing its ability to evade immune clearance and effectively deliver genetic medicines to metastatic tumor sites.

  • Scientific Advisory Board Established: The company formed a new Scientific Advisory Board comprising esteemed experts to support the development of CLD-401 and enhance the capabilities of its RedTail platform for targeted genetic medicine delivery.

  • Financial Update: Calidi raised $6.9 million through a public offering, increasing total gross proceeds for 2025 to $23 million, while reporting a net loss of $5.2 million for Q3 2025, slightly higher than the previous year.

  • Platform Expansion: The RedTail platform's functionality is being expanded with new payloads and programmable membrane targeting, advancing its applications in virotherapy beyond oncology.

[object Object]
Preview
8.5
08-22Newsfilter
Calidi Biotherapeutics Completes $6.9 Million Public Offering with Full Over-Allotment Option Exercised by Underwriters

  • Public Offering Announcement: Calidi Biotherapeutics has successfully closed an underwritten public offering, raising $6.9 million in gross proceeds, including the full exercise of the underwriters' over-allotment option.

  • Details of Securities Sold: The offering included 1,922,764 common stock units and 1,528,000 pre-funded warrant units, with prices set at $2.00 per Common Stock Unit and $1.999 per Pre-Funded Unit.

  • Company Overview: Calidi Biotherapeutics is focused on developing targeted therapies for cancer treatment, utilizing its proprietary Redtail platform to deliver genetic medicines to metastatic sites.

  • Forward-Looking Statements: The press release contains forward-looking statements regarding the company's future developments and potential risks associated with clinical trials and capital raising efforts.

[object Object]
Preview
4.5
08-21Benzinga
Nasdaq Declines 1%; Lowe's Reports Positive Earnings

  • U.S. Stock Market Performance: U.S. stocks declined mid-session, with the Nasdaq Composite dropping over 200 points and the S&P 500 and Dow also experiencing losses.

  • Lowe's Earnings Report: Lowe's Companies reported better-than-expected second-quarter earnings, with adjusted EPS rising to $4.33 and quarterly sales reaching $23.96 billion, prompting an update in fiscal guidance.

  • Equities Movement: NovaBay Pharmaceuticals saw a significant stock increase of 68% after a securities purchase agreement, while enVVeno Medical Corporation shares plummeted 72% following FDA news.

  • Global Market Trends: European shares showed mixed results, Asian markets closed mixed with Japan's Nikkei falling, and U.S. mortgage applications decreased by 1.4% from the previous week.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Calidi Biotherapeutics Inc (CLDI) stock price today?

The current price of CLDI is 1.54 USD — it has increased 2.67 % in the last trading day.

arrow icon

What is Calidi Biotherapeutics Inc (CLDI)'s business?

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

arrow icon

What is the price predicton of CLDI Stock?

Wall Street analysts forecast CLDI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDI is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Calidi Biotherapeutics Inc (CLDI)'s revenue for the last quarter?

Calidi Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Calidi Biotherapeutics Inc (CLDI)'s earnings per share (EPS) for the last quarter?

Calidi Biotherapeutics Inc. EPS for the last quarter amounts to -2.21 USD, decreased -71.48 % YoY.

arrow icon

What changes have occurred in the market's expectations for Calidi Biotherapeutics Inc (CLDI)'s fundamentals?

The market is revising No Change the revenue expectations for CLDI for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -3.75%.
arrow icon

How many employees does Calidi Biotherapeutics Inc (CLDI). have?

Calidi Biotherapeutics Inc (CLDI) has 28 emplpoyees as of December 05 2025.

arrow icon

What is Calidi Biotherapeutics Inc (CLDI) market cap?

Today CLDI has the market capitalization of 11.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free